Wirksamkeit von darmlöslichem   Lecithin (Phosphatidylcholin)   zur Behandlung der Colitis ulcerosa

Stremmel, Wolfgang; Vural, Hüseyín; Evliyaoğlu, Osman; Weiskirchen, Ralf

doi:10.1007/s15006-022-0832-0

Cited by 1 publication

(1 citation statement)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, the administration of a synthetic HDL, carrying a recombinant apolipopro-tein A-IMilano and 1-palmitoyl-2-oleoyl phosphatidylcholine (POPC) protects the isolated rabbit heart from reperfusion injury and significantly reduces fibrosis, decreasing scar size [171]. Interestingly, since ulcerative colitis is considered a risk factor linked to cardiovascular diseases such as accelerated atherosclerosis, atrial fibrillation and heart failure [172,173], using PC enriched enteric lecithin to improve remission rates [174] can decrease corticosteroid dependence [175] and thus reduce stress associated cardiovascular events.…”

Section: Phospholipid Function Experimental Designmentioning

confidence: 99%

Phospholipids, the Masters in the Shadows during Healing after Acute Myocardial Infarction

Pistritu,

Vasiliniuc,

Vasiliu

et al. 2023

IJMS

View full text Add to dashboard Cite

Phospholipids are major components of cell membranes with complex structures, high heterogeneity and critical biological functions and have been used since ancient times to treat cardiovascular disease. Their importance and role were shadowed by the difficulty or incomplete available research methodology to study their biological presence and functionality. This review focuses on the current knowledge about the roles of phospholipids in the pathophysiology and therapy of cardiovascular diseases, which have been increasingly recognized. Used in singular formulation or in inclusive combinations with current drugs, phospholipids proved their positive and valuable effects not only in the protection of myocardial tissue, inflammation and fibrosis but also in angiogenesis, coagulation or cardiac regeneration more frequently in animal models as well as in human pathology. Thus, while mainly neglected by the scientific community, phospholipids present negligible side effects and could represent an ideal target for future therapeutic strategies in healing myocardial infarction. Acknowledging and understanding their mechanisms of action could offer a new perspective into novel therapeutic strategies for patients suffering an acute myocardial infarction, reducing the burden and improving the general social and economic outcome.

show abstract